Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Mar;31(3):1842-1843.
doi: 10.1245/s10434-023-14815-3. Epub 2024 Jan 5.

ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and Nonelevated CA19-9

Thomas F Stoop #  1   2   3 , Deesje Doppenberg #  4   5 , Matthew H G Katz  6 , Ching-Wei D Tzeng  6 , Alice C Wei  7 , Amer H Zureikat  8 , Bas Groot Koerkamp #  9 , Marc G Besselink #  10   11 ; Trans-Atlantic Pancreatic Surgery (TAPS) Consortium
Collaborators, Affiliations
Comment

ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and Nonelevated CA19-9

Thomas F Stoop et al. Ann Surg Oncol. 2024 Mar.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Oba A, Del Chiaro M, Satoi S, et al. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS) J Hepatobiliary Pancreat Sci. 2022;29(7):725–731. doi: 10.1002/jhbp.1049. - DOI - PubMed
    1. Stoop TF, Theijse RT, Seelen LWF, et al. Preoperative chemotherapy, radiotherapy, and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2023 doi: 10.1038/241575-023-00856-2. - DOI - PubMed
    1. Bergquist JR, Puig CA, Shubert CR, et al. Carbohydrate antigen 19–9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: A national cancer database study. J Am Coll Surg. 2016;223(1):52–65. doi: 10.1016/j.jamcollsurg.2016.02.009. - DOI - PubMed
    1. Doppenberg D, Stoop TF, van Dieren S, et al. Serum CEA as prognostic marker for overall survival in patients with localized pancreatic adenocarcinoma and non-elevated CA19-9 levels treated with FOLFIRINOX as initial treatment: a TAPS consortium study. Ann Surg Oncol. 2023 doi: 10.1245/s10434-023-14680-0. - DOI - PubMed
    1. Kinny-Köster B, Habib J, Wolfgang CL, He J, Javed AA. Favorable tumor biology in locally advanced pancreatic cancer: Beyond CA19-9. J Gastrointest Oncol. 2021;12(5):2484–2494. doi: 10.21037/jgo-20-426. - DOI - PMC - PubMed